Atacand
(Candesartan Cilexetil)ApprovedSmall molecule
Atacand is a small molecule that works as a Type-1 Angiotensin II Receptor Antagonist.[2] It is being used across 20 indications, with its most advanced program in Approved.[1]
Atacand is one of 498 small molecule programs targeting Metabolic Syndrome. It is currently in Approved.
20
Indications
39
Total Trials
1
Active Trials
497
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 19 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Atacand
IIstituto Clinico Humanitas
Approved
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Preclinical
MS Contin
Merck & Co.Preclinical
Adenocard
AstellasPreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Effexor
WWyeth-Lederle Vaccines
Preclinical
Recentin
NNational Cancer Institute (NCI)
Preclinical
Acupan
YYonsei University
Preclinical
Avastin
RochePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Essential Hypertension7 trials
Efficacy and Safety5 trials
Hypertensive3 trials
Fasting Conditions3 trials
18 more indications
Observational Study1 trial
Brain Injury1 trial
Interaction1 trial
Atorvastatin1 trial
Cardiovascular Events1 trial
Type 2 Diabetes Mellitus1 trial
Metabolic Syndrome1 trial
COVID-191 trial
Unspecified2 trials
Regulatory
FDA Approval Timeline[4]
Jun 4, 1998
ATACAND
NDA NDA020838
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Candesartan Cilexetil. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Type-1 Angiotensin II Receptor Antagonist[2]
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- IIstituto Clinico Humanitas